FutureHorizons

FH MONDAY

30 January 2023



Future Horizons Ltd, • 44 Bethel Road • Sevenoaks • Kent TN13 3UE • England Tel: +44 1732 740440 • Fax: +44 1732 740442 e-mail: <u>mail@futurehorizons.com</u>• <u>http://www.futurehorizons.com/</u> Affiliates in Europe, India, Israel, Japan, Russian, San Jose California, USA

France to Invest €500M in Deeptech Startups by 2030

France is struggling to turn scientific discoveries into innovations, and the number of startups arising from research projects remains below expectations. In response, the French government has announced it will invest another €500 million in order to create 500 deeptech startups per year and 100 unicorns in France by 2030.

This move is an integral part of "France 2030," an investment plan launched in October 2021 to revive France's industrial economy and to create future technological champions in strategic sectors such as semiconductors, robotics, electric vehicles, nuclear, and renewable energy sources. "France 2030", announced around €30 billion in October 2021 now officially amounts to €54 billion.

In early 2019, the French government launched the Deeptech Plan to develop breakthrough innovations in France.

LioniX International Secures €3.5M Investment to Drive Growth

The Netherlands continues to strive for a prominent position on the European and global photonics scenes. A consortium of Dutch investors has invested €3.5 million in LioniX International, an Enschede-based provider of photonic integrated circuit modules and customized MEMS.

LioniX International was formed from three Dutch startups: Satrax, XiO Photonics and LioniX. LioniX was founded as Lion Photonics in 2001 by Hans van De Vlekkert and René Heideman, who are still part of the LioniX International management team.

In 2016, LioniX absorbed Satrax and XiO Photonics to become LioniX International. In 2018, South Korean electronic component company Magic Micro acquired a majority stake of 75% in LioniX International and provided the company with 6- and 8-inch high-volume clean room facilities, enabling a transition from the 4-inch fabrication facilities in the Netherlands to high-volume PIC manufacturing in Korea.

TETHER Enables Tata Motors' Connected Vehicle Platform to Scale New Heights

Tata Motors Ltd has crossed a significant milestone of onboarding 500,000 vehicles onto Tata Elxsi's TETHER Connected Vehicle Platform (CVP) that caters to its entire range of commercial, passenger and electric vehicles (EVs).

In early 2019, Tata Motors collaborated with Tata Elxsi to adopt and adapt the TETHER CVP toward a common standard technology stack to deliver scalability, differentiated features, high performance, and expandable to Industry 4.0 to transform their internal operations.

Innovative ASIC CPU Drives Record-Setting Server Performance

In a paper presented at the TSMC North America Open Innovation Platform Forum, Alchip Technologies and Synopsys showed how collaborative design expertise, EDA tools, and high-quality IP had created a record-setting, high-performance artificial intelligence enabled data center system-on-a chip (SoC).

The paper, being presented at TSMC OIP Forums in North America, Europe, and China, explains how the two companies developed a new high-performance SoC to operate to specification under extremely challenging 400-watt dynamic power conditions. The device also achieved first-pass silicon success on TSMC's 7nm process technology.

Imec Crafting Tools to Treat Cancer, Sequence Proteomes

LEUVEN, Belgium—Imec, a research center for nanoelectronics and digital technologies based here, is developing tools, modules and nanochips with the goals of advancing cancer treatment, sequencing proteomes and better understanding the brain, Peter Peumans, imec's CTO for health technologies, told EE Times.

One project focuses on improving the groundbreaking adoptive cell cancer therapy called chimeric antigen receptor (CAR) T-cell therapy, which involves removing a patient's T-cells, reprogramming those cells so they can recognize and kill a cancerous tumor, multiplying the cells and then injecting the modified cells into the patient's body to hunt down and eliminate cancer cells, he said. The treatment is effective with an up to 90% remission rate, but it's also quite expensive: hundreds of thousands of dollars.